| Aktienanzahl | 34,96 Mio. |
| Aktientyp | Stammaktie |
The FDA's Center for Veterinary Medicine approves Aratana Therapeutics' (NASDAQ:PETX) NOCITA (bupivacaine liposome injectable suspension) for local post-operative analgesia in dogs following cranial cruciate ligament surgery.NOCITA is a local anesthetic that lasts up to 72 hours after surgery by slowly releasing bupivacaine over time. It is administered in a single dose by tissue infiltration during wound closure.
Der Aktienkurs ist nach Handelsschluss um 5% gestiegen.